[1] Rinninella AE, Raoul P, Cintoni M, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms, 2019,7(1):1-22.
[2] Philips C A, Augustine P. Gut barrier and microbiota in cirrhosis. J Clin Exp Hepatol, 2022,12(2): 625-638.
[3] Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology, 2011,54(2): 562-572.
[4] Kakiyama G, Pandak W M, Gillevet P M, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol, 2013,58(5): 949-955.
[5] Shah A, Shanahan E, Macdonald G A, et al. Systematic review and Meta-analysis: Prevalence of small intestinal bacterial overgrowth in chronic liver disease. Semin Liver Dis, 2017,37(4): 388-400.
[6] Li F, Mcclain C J, Feng W. Microbiome dysbiosis and alcoholic liver disease. Liver Res, 2019,3(3-4): 218-226.
[7] Bajaj J S, Heuman D M, Hylemon P B, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol, 2014,60(5): 940-947.
[8] Bajaj J S, Vargas H E, Reddy K R, et al. Association between intestinal microbiota collected at hospital admission and outcomes of patients with cirrhosis. Clin Gastroenterol Hepatol, 2019,17(4): 756-765.
[9] Bajaj J S, Ridlon J M, Hylemon P B, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol, 2012,302(1): G168-G175.
[10] Ahluwalia V, Betrapally N S, Hylemon P B, et al. Impaired gut-liver-brain axis in patients with cirrhosis. Sci Rep, 2016,6: 26800.
[11] Acharya C, Bajaj J S. Altered microbiome in patients with cirrhosis and complications. Clin Gastroenterol Hepatol, 2019,17(2): 307-321.
[12] Acharya C, Sahingur S E, Bajaj J S. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight, 2017,2(19):156-160.
[13] Philips C A, Ganesan K, Ranade S, et al. IDDF2020-ABS-0038 Analysis and identification of disruptive gut microbiota and its perturbed metabolic functions and recognition of potential novel therapeutic targets in decompensated cirrhosis with sepsis. Gut, 2020,69(Suppl 2): A9.
[14] Zhang Z, Zhai H, Geng J, et al. Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing. Am J Gastroenterol, 2013,108(10): 1601-1611.
[15] Gowser F, MunchP, Lesker T R, et al. Neither black nor white: do altered intestinal microbiota reflect chronic liver disease severity? Gut, 2021,70(2): 438-440.
[16] Bajaj J S, Liu E J, Kheradman R, et al. Fungal dysbiosis in cirrhosis. Gut, 2018,67(6): 1146-1154.
[17] Bajaj J S, Idilman R, Mabudian L, et al. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. Hepatology, 2018,68(1): 234-247.
[18] Zoratti C, Moretti R, Rebuzzi L, et al. Antibiotics and liver cirrhosis: What the physicians need to know. Antibiotics (Basel), 2021,11(1):623-627.
[19] Horvath A, Durdevic M, Leber B, et al. Changes in the intestinal microbiome during a multispecies probiotic intervention in compensated cirrhosis. Nutrients, 2020,12(6):362-366.
[20] Han S H, Suk K T, Kim D J, et al. Effects of probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study. Eur J Gastroenterol Hepatol, 2015,27(11): 1300-1306.
[21] Lee N Y, Suk K T. The Role of the gut microbiome in liver cirrhosis treatment. Int J Mol Sci, 2020,22(1):48-53.
[22] Hassouneh R, Bajaj J S. Gut microbiota modulation and fecal transplantation: An overview on innovative strategies for hepatic encephalopathy treatment. J Clin Med, 2021,10(2):148-153.
[23] Bajaj J S, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology, 2017,66(6): 1727-1738.
[24] Bajaj J S, Fagan A, Gavis E A, et al. Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis. Gastroenterology, 2019,156(6): 1921-1923.
[25] Bajaj J S, Salzman N H, Acharya C, et al. Fecal mTransplant capsules are safe in hepatic encephalopathy: A phase 1, randomized, placebo-controlled trial. Hepatology, 2019,70(5): 1690-1703.
[26] Mehta R, Kabrawala M, Nandwani S, et al. Preliminary experience with single fecal microbiota transplant for treatment of recurrent overt hepatic encephalopathy-A case series. Indian J Gastroenterol, 2018,37(6): 559-562.
[27] Bajaj J S, Kakiyama G, Savidge T, et al. Antibiotic-associated disruption of microbiota composition and function in cirrhosis is restored by fecal transplant. Hepatology, 2018,68(4): 1549-1558.
[28] Bajaj J S, Shamsaddini A, Fagan A, et al. Fecal microbiota transplant in cirrhosis reduces gut microbial antibiotic resistance genes: Analysis of two trials. Hepatol Commun, 2021,5(2): 258-271.
[29] Philips C A, Pande A, Shasthry S M, et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: A pilot study. Clin Gastroenterol Hepatol, 2017,15(4): 600-602.
[30] Philips C A, Phadke N, Ganesan K, et al. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis. Indian J Gastroenterol, 2018,37(3): 215-225.
[31] Philips C A, Augustine P, Padsalgt G, et al. Only in the darkness can you see the stars: Severe alcoholic hepatitis and higher grades of acute-on-chronic liver failure. J Hepatol, 2019,70(3): 550-551.
[32] Bajaj J S, Gavis E A, Fagan A, et al. A randomized clinical trial of fecal microbiota transplant for alcohol use disorder. Hepatology, 2021,73(5): 1688-1700. |
